UOC
RCUS icon

UBS O'Connor’s Arcus Biosciences RCUS Stock Holding History

UBS O'Connor’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-52,975
Closed -$431K – 419
2025
Q2 		$431K Sell
52,975
-75,713
-59% -$647K 0.01% 278
2025
Q1 		$1.01M Buy
128,688
+52,042
+68% +$603K 0.02% 187
2024
Q4 		$1.14M Buy
76,646
+44,784
+141% +$731K 0.03% 215
2024
Q3 		$487K Sell
31,862
-33,325
-51% -$525K 0.01% 346
2024
Q2 		$993K Buy
65,187
+1,065
+2% +$17.2K 0.03% 297
2024
Q1 		$1.21M Buy
64,122
+10,876
+20% +$188K 0.03% 257
2023
Q4 		$1.02M Sell
53,246
-46,166
-46% -$738K 0.03% 267
2023
Q3 		$1.78M Sell
99,412
-5,000
-5% -$100K 0.03% 261
2023
Q2 		$2.12M Sell
104,412
-10,068
-9% -$192K 0.04% 284
2023
Q1 		$2.09M Buy
114,480
+87,655
+327% +$1.68M 0.05% 306
2022
Q4 		$555K Sell
26,825
-11,900
-31% -$327K 0.01% 610
2022
Q3 		$1.01M Sell
38,725
-11,700
-23% -$309K 0.01% 748
2022
Q2 		$1.28M Buy
+50,425
New +$1.23M 0.01% 736

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS O'Connor's RCUS Position: Q3 2025 in Review

UBS O'Connor sold out of Arcus Biosciences (RCUS) in Q3 2025, closing a stake of 52,975 shares — an estimated $431K sold.

UBS O'Connor first reported a position in RCUS in Q2 2022 and held it in 13 quarters. The position peaked at $2.12M in Q2 2023. 190 funds tracked by Wall St. Rank hold RCUS as of Q3 2025.

  • UBS O'Connor reported no remaining Arcus Biosciences position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 52,975 Arcus Biosciences shares in Q3 2025, an estimated $431K.
  • UBS O'Connor first reported a position in Arcus Biosciences in Q2 2022 and held it in 13 quarters.
  • UBS O'Connor's Arcus Biosciences position peaked at $2.12M in Q2 2023.
  • 190 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.